Microarchitectural deterioration of cortical and trabecular bone: Differing effects of denosumab and alendronate

The intensity of bone remodeling is a critical determinant of the decay of cortical and trabecular microstructure after menopause. Denosumab suppresses remodeling more than alendronate, leading to greater gains in areal bone mineral density (aBMD). These greater gains may reflect differing effects o...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of bone and mineral research 2010-08, Vol.25 (8), p.1886-1894
Hauptverfasser:	Seeman, Ego, Delmas, Pierre D, Hanley, David A, Sellmeyer, Deborah, Cheung, Angela M, Shane, Elizabeth, Kearns, Ann, Thomas, Thierry, Boyd, Steven K, Boutroy, Stephanie, Bogado, Cesar, Majumdar, Sharmila, Fan, Michelle, Libanati, Cesar, Zanchetta, Jose
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged alendronate Alendronate - administration & dosage Alendronate - adverse effects Alendronate - pharmacology Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal, Humanized Biological and medical sciences Biomarkers - metabolism Bone and Bones - diagnostic imaging Bone and Bones - drug effects Bone and Bones - pathology Bone Density - drug effects Bone Density Conservation Agents - administration & dosage Bone Density Conservation Agents - adverse effects Bone Density Conservation Agents - pharmacology Bone Remodeling - drug effects cortical thickness Demography Denosumab Female Fundamental and applied biological sciences. Psychology HR‐pQCT Humans Middle Aged Original RANK Ligand - administration & dosage RANK Ligand - adverse effects RANK Ligand - pharmacology Skeleton and joints Tomography, X-Ray Computed Vertebrates: osteoarticular system, musculoskeletal system volumetric bone mineral density
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!